Brazil’s well being regulator Anvisa stated on Wednesday that the demise of a 16-year-old man who obtained the primary dose of the Pfizer/BioNTech vaccine in opposition to COVID-19 was not beforehand associated to a blood clotting situation.
Concluding the investigation into the demise that occurred earlier this month, Anvisa stated it was as a result of juvenile’s auto-immune illness.
The Pfizer vaccine is the one vaccine authorized for minors in Brazil. “This was a typical clinical picture of thrombotic thrombocytopenic purpura, an autoimmune disease,” the regulator stated in an announcement.
Thrombotic thrombocytopenic purpura is a uncommon dysfunction that causes blood clots to kind in small blood vessels all through the physique that may trigger severe medical issues in the event that they limit blood movement to organs such because the mind, kidneys or coronary heart.
Concern over COVID-19 vaccines and blood clots has prompted investigations by researchers around the globe.
The European Commission requested scientific opinion from the European Medicines Agency (EMA) on whether or not girls and younger adults have been at increased danger of blood clots after vaccination with AstraZeneca’s COVID-19 shot.
The EMA couldn’t affirm whether or not this was the case. Brazil’s federal authorities final week sought to halt COVID-19 vaccinations for teenagers whereas the demise was being investigated as a suspected antagonistic occasion, however a number of state governments vowed to pressurize.
About 3.5 million Brazilians aged 12 to 17 have already been immunized.
With inputs from TheIndianEXPRESS